Non-invasive risk-based surveillance of HCC in patients with MASLD скачать в хорошем качестве

Non-invasive risk-based surveillance of HCC in patients with MASLD

To cite: Lai JC, Yang B, Lee HW, et al. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. Gut 2025;74:2050-2057. Read the full article here: https://doi.org/10.1136/gutjnl-2025-3... Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the general population and is the fastest growing cause of hepatocellular carcinoma (HCC). Current guidelines recommend HCC surveillance in patients with cirrhosis when annual HCC incidence exceeds 1% without specifying the role of non-invasive tests in patient selection. Conclusion: HCC surveillance should be offered to patients with MASLD with FIB-4 ≥3.25 or LSM ≥20 kPa. When a two-step approach is adopted, LSM ≥15 kPa in patients with increased FIB-4 predicts a high HCC risk.